Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China

被引:7
|
作者
Li, Heng
Xiong, Wenjie
Liu, Huimin
Yi, Shuhua
Yu, Zhen
Liu, Wei
Lyu, Rui
Wang, Tingyu
Zou, Dehui
Li, Zengjun
Qiu, Lugui
机构
[1] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci, Dept Lymphoma & Myeloma, Inst Hematol, Tianjin 300020, Peoples R China
关键词
17p deletion; chronic lymphocytic leukemia (CLL); fluorescent in situ hybridization (FISH); del17p in CLL; HIGH-DOSE METHYLPREDNISOLONE; LRF CLL4 TRIAL; RITUXIMAB; THERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL; ABNORMALITIES; ALEMTUZUMAB; ABERRATIONS;
D O I
10.21147/j.issn.1000-9604.2017.02.09
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia (CLL) and a 17p deletion (17p-) and identify the predictive factors within this subgroup. Methods: The sample of patients with CLL were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 11q22, 13q14 and 17p13; trisomy of bands 12q13; and translocation involving band 14q32. The data from 456 patients with or without a 17p-were retrospectively collected and analyzed. Results: The overall response rate (ORR) in patients with a 17p- was 56.9%, and patients with a high percentage of 17p-(defined as more than 25% of cells harbouring a 17p-) had a lower ORR. The median overall survival (OS) in patients with a 17p-was 78.0 months, which was significantly shorter than the OS in patients without this genetic abnormality (median 162.0 months, P<0.001). Within the subgroup with a 17p-, the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase (LDH), B symptoms, unmutated IGHV and a high percentage of 17p-. Conclusions: These results indicated that patients with a 17p- CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics.
引用
收藏
页码:156 / 165
页数:10
相关论文
共 50 条
  • [21] A case of chronic lymphocytic leukemia with deletion 17p and bilateral retinal leukemic infiltrates
    Treppendahl, Marianne Bach
    Andersen, Nis
    Jurlander, Jesper
    Geisler, Christian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (01) : 79 - 80
  • [22] REAL-WORLD OUTCOMES OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
    Lamanna, N.
    Hurst, D.
    Latremouille-Viau, D.
    Ionescu-Ittu, R.
    Guerin, A.
    Yim, Y. M.
    Reyes, C.
    HAEMATOLOGICA, 2015, 100 : 421 - 422
  • [23] Clinicohematological parameters and outcomes in a cohort of chronic lymphocytic leukemia patients with Deletion 17p from Pakistan
    Mahmood, Rafia
    Khan, Saleem Ahmed
    Altaf, Chaudhry
    Malik, Hamid Saeed
    Khadim, Muhammad Tahir
    BLOOD RESEARCH, 2018, 53 (04) : 276 - 280
  • [24] The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients
    Tam, C. S.
    Wierda, W.
    O'Brien, S. M.
    Lerner, S.
    Abruzzo, L. V.
    Ferrajoli, A.
    Kantarjian, H. M.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion
    Strati, Paolo
    Keating, Michael J.
    O'Brien, Susan M.
    Ferrajoli, Alessandra
    Burger, Jan
    Faderl, Stefan
    Tambaro, Francesco Paolo
    Jain, Nitin
    Wierda, William G.
    HAEMATOLOGICA, 2014, 99 (08) : 1350 - 1355
  • [26] Allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia with 17p Deletion:: a retrospective EBMT analysis
    Schetelig, J.
    van Biezen, A.
    Brand, R.
    Caballero, D.
    Martino, R.
    Itala, M.
    Garcia-Marco, J.
    Volin, L.
    Schmitz, N.
    Schwerdtfeger, R.
    Ganser, A.
    Onida, F.
    Mohr, B.
    Stilgenbauer, S.
    Bornhaeuser, M.
    de Witte, T.
    Dreger, P.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S52 - S52
  • [27] CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia
    Chevallier, P
    Penther, D
    Avet-Loiseau, H
    Robillard, N
    Ifrah, N
    Mahé, B
    Hamidou, M
    Maisonneuve, H
    Moreau, P
    Jardel, H
    Harousseau, JL
    Bataille, R
    Garand, R
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (01) : 142 - 150
  • [28] SUCCESSFUL TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA SHOWING 17P DELETION WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND ALEMTUZUMAB
    Montillo, M.
    Tedeschi, A.
    Ricci, F.
    Miqueleiz, S.
    Vismara, E.
    Greco, A.
    Colombo, C.
    Mura, M. A.
    Veronese, S.
    Morra, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 370 - 371
  • [29] Treatment Outcomes Among Chronic Lymphocytic Leukemia Patients with 17p Deletion or TP53 Mutation in Argentina: A Retrospective Chart Review
    Pavlovsky, Miguel A.
    Sail, Kavita
    Chaves, Leonardo Passos
    Kamalakar, Rajesh
    Ma, Xiaojing
    Brandalise, Patricia
    Chiattone, Carlos
    BLOOD, 2017, 130
  • [30] Detailed Molecular Analysis of Patients with Chronic Lymphocytic Leukemia Carrying 17p Deletions Reveals Concurrent Abnormalities with Prognostic Impact
    Delgado, Julio
    Salaverria, Itziar
    Lee, Eriong
    Jimenez, Laura
    Navarro, Alba
    Colomer, Dolors
    Dlouhy, Ivan
    Conde, Laura
    Martinez-Trillos, Alejandra
    Lopez, Cristina
    Villamor, Neus
    Aymerich, Marta
    Rozman, Maria
    Gine, Eva
    Costa, Dolors
    Carrio, Anna
    Lopez-Guillermo, Armando
    Campo, Elias
    Bea, Slvia
    BLOOD, 2012, 120 (21)